1340 - Phase II study of erlotinib in Japanese patients with pretreated EGFR mutation positive non-small cell lung cancer: Lung Oncology Group in Kyushu, J...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Koichi Takayama
Authors K. Takayama1, Y. Nakanishi1, S. Kawakami2, K. Saruwatari3, K. Yamada4, R. Morinaga5, N. Aragane6, S. Nagata7, J. Kishimoto8, Y. Ichinose9
  • 1Research Institute For Diseases Of The Chest, Kyushu University, 8128582 - Fukuoka/JP
  • 2Respirology, Kyushu Kosei-Nenkin Hospital, 8068501 - Kitakyusyu/JP
  • 3Respiratory Medicine, Kumamoto University, 8608556 - Kumamoto/JP
  • 4Division Of Respirology, Kurume University, 8300011 - Kurume/JP
  • 5Medical Oncology, Oita University Faculty of Medicine, 879-5593 - Oita/JP
  • 6Blood And Lung And Tumor Instituite, Saga University, 8498501 - Saga/JP
  • 7Respiratory Medicine, University of Occupational and Environmental Health, 8078555 - Kitakyusyu/JP
  • 8Center For Clinical And Translational Research, Kyushu University Hospital, 8128582 - Fukuoka/JP
  • 9Clinical Research Institute, National Kyushu Cancer Center, JP-811-1395 - Fukuoka/JP

Abstract

Background

Erlotinib has been reported to be useful for treating EGFR mutation-positive (EGFR-mt) non-small cell lung cancer (NSCLC) (OPTIMAL ESMO 2010, EURTAC Lancet Oncol. 2012). However, its usefulness had not been investigated in Japanese patients. Hence, we conducted a multicenter phase II study to investigate the efficacy and safety of erlotinib in Japanese patients with pretreated EGFR-mt NSCLC.

Methods

Erlotinib, 150 mg/day, was orally administered daily to patients with pretreated EGFR-mt (exon 19/21) NSCLC who had not been treated with EGFR-TKIs. The primary endpoint was objective response rate (ORR), and the secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and safety.

Results

Between April 2009 and January 2011, 26 patients were enrolled from 15 participating centers. The patient characteristics were as follows: median age, 68 years (51 to 79); men/women, 11/15; adenocarcinoma/others, 24/2; nonsmoking/smoking, 20/6; ECOG PS 0/1/2, 16/8/2; exon 19/21, 19/7; and 2nd/3rd line therapy, 25/1. The antitumor effect was as follows: PR, 14 patients; SD, 7 patients; PD, 4 patients; NE, 1 patient; ORR, 54%; and DCR, 81%. The ORR and DCR according to the EGFR status were 47.4%/71.4% (exon 19/21, p = 0.3913) and 73.7%/100% (p = 0.2782), respectively. The PFS was 9.3 months (range, 0.9 to 19.2 mo). Major adverse drug reactions were rash (96%) and hepatic function disorder (40%); most episodes were grade 2 or less, and all were tolerable. No patients developed interstitial lung disease, and there were no treatment-related deaths.

Conclusion

In this study, the usefulness of erlotinib was investigated prospectively in Japanese patients with pretreated EGFR-mt NSCLC for the first time, and this drug was shown to be effective and tolerable. At this congress, we will report the study results including the ORR and PFS according to the patient characteristics.

Disclosure

Y. Nakanishi: From Chugai Pharmaceutical, I received 7500 Euro as honoraria on 2011, and 22000 Euro on 2010 and 70000 Euro on 2011 as research grant.

Y. Ichinose: I have research funding with Chugai Pharmaceutical company.

All other authors have declared no conflicts of interest.